285 related articles for article (PubMed ID: 16371460)
1. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.
Grbovic OM; Basso AD; Sawai A; Ye Q; Friedlander P; Solit D; Rosen N
Proc Natl Acad Sci U S A; 2006 Jan; 103(1):57-62. PubMed ID: 16371460
[TBL] [Abstract][Full Text] [Related]
2. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
3. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
[TBL] [Abstract][Full Text] [Related]
4. p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function.
Grammatikakis N; Lin JH; Grammatikakis A; Tsichlis PN; Cochran BH
Mol Cell Biol; 1999 Mar; 19(3):1661-72. PubMed ID: 10022854
[TBL] [Abstract][Full Text] [Related]
5. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
[TBL] [Abstract][Full Text] [Related]
6. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
Burger AM; Fiebig HH; Stinson SF; Sausville EA
Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143
[TBL] [Abstract][Full Text] [Related]
7. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.
Hostein I; Robertson D; DiStefano F; Workman P; Clarke PA
Cancer Res; 2001 May; 61(10):4003-9. PubMed ID: 11358818
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC
Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P
Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
Solit DB; Osman I; Polsky D; Panageas KS; Daud A; Goydos JS; Teitcher J; Wolchok JD; Germino FJ; Krown SE; Coit D; Rosen N; Chapman PB
Clin Cancer Res; 2008 Dec; 14(24):8302-7. PubMed ID: 19088048
[TBL] [Abstract][Full Text] [Related]
12. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
13. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.
Wu X; Marmarelis ME; Hodi FS
PLoS One; 2013; 8(2):e56134. PubMed ID: 23418523
[TBL] [Abstract][Full Text] [Related]
14. Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites.
Eckl JM; Scherr MJ; Freiburger L; Daake MA; Sattler M; Richter K
J Biol Chem; 2015 Dec; 290(52):30843-54. PubMed ID: 26511315
[TBL] [Abstract][Full Text] [Related]
15. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
16. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Schulte TW; Neckers LM
Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
[TBL] [Abstract][Full Text] [Related]
17. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.
Sharma A; Madhunapantula SV; Gowda R; Berg A; Neves RI; Robertson GP
Am J Pathol; 2013 Apr; 182(4):1151-62. PubMed ID: 23416158
[TBL] [Abstract][Full Text] [Related]
18. Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.
Smith JR; de Billy E; Hobbs S; Powers M; Prodromou C; Pearl L; Clarke PA; Workman P
Oncogene; 2015 Jan; 34(1):15-26. PubMed ID: 24292678
[TBL] [Abstract][Full Text] [Related]
19. Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling.
Zhang H; Wu W; Du Y; Santos SJ; Conrad SE; Watson JT; Grammatikakis N; Gallo KA
J Biol Chem; 2004 May; 279(19):19457-63. PubMed ID: 15001580
[TBL] [Abstract][Full Text] [Related]
20. Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte.
Ota A; Zhang J; Ping P; Han J; Wang Y
Circ Res; 2010 Apr; 106(8):1404-12. PubMed ID: 20299663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
